Nerandomilast not checked
Boehringer Ingelheim · BI 1015550
FollowEvery change as it happens, and a Monday email
Trials
7 active
32 in total · 14 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Interstitial Lung Diseases (3 trials), Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Fibrosing Interstitial Lung Disease, Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Systemic Sclerosis and 1 more
- Main trialPhase 3
- “Adults 18 years of age and older or above legal age with lung fibrosis related to systemic autoimmune rheumatic disease can participate in this study. People can only take part if they show no improvement in lung function after standard treatment with immunosuppressant medicine. The main purpose of this study is to find out how a medicine called nerandomilast affects the lungs in people with systemic autoimmune rheumatic disease. Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets…”In the company’s words, NCT06806592 on ClinicalTrials.gov
- Other names
- BI 1015550 · JASCAYD
Other drugs for Interstitial Lung Diseases
- MosliciguatPulmovant, Inc. · Phase 3
- SC1011JOYO Pharma · Phase 2/3
- AnifrolumabAstraZeneca · Phase 3
- OlokizumabR-Pharm International, LLC · Phase 2/3
- NAL ERTrevi Therapeutics · Phase 3
- TreprostinilUnited Therapeutics · Phase 3
Coming up7
- 15 Apr 2027Phase 3 trial completes · ClinicalTrials.gov
- 28 Apr 2027Phase 3 trial completes · ClinicalTrials.gov
- 5 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
- 27 Apr 2029Phase 3 trial completes · ClinicalTrials.gov
- 14 May 2029Phase 3 trial completes · ClinicalTrials.gov
- 26 Feb 2030Phase 3 trial completes · ClinicalTrials.gov
- 21 Mar 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials32
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 15 Apr 2027 | A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases | |
| Phase 3Active, not recruiting | 28 Apr 2027 | A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | |
| Phase 3Recruiting | 5 Dec 2028 | FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression | |
| Phase 3Recruiting | 27 Apr 2029 | A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD) | |
| Phase 3Recruiting | 14 May 2029 | A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis | |
| Phase 3Recruiting | 26 Feb 2030 | A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis | |
| Phase 3Not yet recruiting | 21 Mar 2030 | A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies | |
| Phase 3Completed | 16 Aug 2024 | A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) | |
| Phase 3Completed | 18 Dec 2024 | A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | |
| Phase 2Completed | 6 Oct 2021 | A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) | |
| Phase 2Completed | 5 Aug 2026 | A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood | |
| Phase 1Completed | 13 Dec 2017 | Relative Bioavailability of BI 1015550 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects | |
| Phase 1Completed | 16 Jan 2018 | This Study Tests How Healthy Men Tolerate Different Doses of BI1015550. The Study Also Tests How BI 1015550 is Taken up by the Body | |
| Phase 1Completed | 20 Jul 2018 | This Study in Healthy Men Tests How Itraconazole Influences the Amount of BI 1015550 in the Blood | |
| Phase 1Completed | 24 Aug 2018 | This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 1015550 Are Taken up in the Body and How Well They Are Tolerated. | |
| Phase 1Completed | 1 Jul 2019 | This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated. | |
| Phase 1Completed | 17 May 2021 | A Study in Healthy Men to Find Out How BI 1015550 is Taken up and Handled by the Body | |
| Phase 1Completed | 30 Sep 2022 | A Study in Healthy People to Compare 2 Different Formulations of BI 1015550 Taken With or Without Food | |
| Phase 1Completed | 19 Dec 2022 | A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Midazolam in the Blood | |
| Phase 1Completed | 16 Mar 2023 | A Study in Healthy Chinese People to Test How Different Doses of BI 1015550 Are Taken up in the Body | |
| Phase 1Completed | 28 Mar 2023 | A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body | |
| Phase 1Completed | 15 Aug 2023 | A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Kidney Problems | |
| Phase 1Completed | 13 Sep 2023 | A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems | |
| Phase 1Completed | 14 Dec 2023 | A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood | |
| Phase 1Completed | 7 Feb 2024 | A Study to Test How Different Doses of Nerandomilast (BI 1015550) Are Taken up in the Body of Healthy Japanese Men | |
| Phase 1Completed | 24 Jul 2024 | A Study in Healthy People to Test How BI 1015550 is Taken up in the Body When Given With or Without Food | |
| Phase 1Completed | 25 Jul 2024 | A Study in Healthy People to Test Whether Different Doses of BI 1015550 Have Potential to Induce Heart Rhythm Abnormalities | |
| Phase 1Completed | 28 Aug 2024 | A Study in Healthy People to Compare How 2 Different Low Dose Formulations of BI 1015550 Are Taken up in the Body | |
| Phase 1Completed | 10 Sep 2024 | A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body | |
| Phase 1Completed | 22 Nov 2024 | A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without Food | |
| Phase 1Completed | 20 Sep 2025 | A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Nerandomilast in the Blood | |
| Phase 1Completed | 27 Sep 2025 | A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026